2026-07-22T05:26:33Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/188722024-03-05T07:43:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Ramos Rincón, José Manuel author Pérez-Belmonte, Luis M. author Carrasco-Sánchez, Francisco Javier author Jansen-Chaparro, Sergio author De-Sousa-Baena, Mercedes author Bueno-Fonseca, José author Pérez-Aguilar, Maria author Arévalo-Cañas, Coral author Bacete Cebrian, Marta author Méndez Bailón, Manuel author Fiteni Mera, Isabel author González García, Andrés author Navarro Romero, Francisco author Tuñón de Almeida, Carlota author Muñiz Nicolás, Gemma author Gonzáez Noya, Amara author Hernández Milian, Almudena author García-García, Gema-María author Alcalá-Pedrajas, José-Nicolás author Herrero García, Virginia author Corral-Gudino, Luis author Comas Casanova, Pere author Meijide Mírguez, Héctor author Casas Rojo, José Manuel author Gómez Huelgas, Ricardo author SEMI-COVID-19 Network author 2021 Background: The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ?80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. Method: We conducted a nationwide, multicenter, observational study in patients ?80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Results: Of the 2 763 patients ?80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. Conclusions: We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality. 10.1093/gerona/glab124 1758-535X The journals of gerontology. Series A, Biological sciences and medical sciences http://hdl.handle.net/10668/17741 33945610 http://hdl.handle.net/20.500.12105/18872 Age ≥ 80 Cardiometabolic therapy Coronavirus disease-2019 Mortality Type 2 diabetes Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19